We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
- Authors
Yosipovitch, Gil; Lio, Peter A; Rosmarin, David; Serra-Baldrich, Esther; Legat, Franz J; Casillas, Marta; Pierce, Evangeline; Liu, Zhuqing; Sun, Luna; Elmaraghy, Hany; Ständer, Sonja
- Abstract
The article discusses the results of two phase III clinical trials, ADvocate1 and ADvocate2, which examined the efficacy and safety of lebrikizumab monotherapy in patients with moderate-to-severe atopic dermatitis (AD). The trials found that lebrikizumab significantly improved patient-reported itch and reduced sleep loss due to itch. The improvements in itch and sleep loss were observed as early as the first few days of treatment and were consistent with previous studies on lebrikizumab. The study was funded by Dermira, a subsidiary of Eli Lilly and Company, and medical writing assistance was provided by ProScribe–Envision Pharma Group.
- Subjects
CLINICAL trials; ITCHING; ATOPIC dermatitis; SLEEP
- Publication
British Journal of Dermatology, 2024, Vol 190, Issue 2, p289
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1093/bjd/ljad435